Serum magnesium and high-sensitivity C-reactive protein as a predictor for gestational diabetes mellitus in Sudanese pregnant women

Warda Naser1, Ishag Adam2, Duria A. Rayis2, Mohammed A. Ahmed2 and Hamdan Z. Hamdan1,3*

Abstract

Background: Gestational diabetes mellitus (GDM) is a big health problem that adversely affects both the maternal and perinatal outcomes. We aimed to predict the development of GDM in the first trimester using high sensitivity C-reactive protein (hs-CRP) and serum magnesium.

Methods: The study conducted in the antenatal care clinic of Saad Abualila Hospital (Khartoum, Sudan). Pregnant women were enrolled in this longitudinal cohort study during first trimester ≤14 weeks of gestation. Serum hs-CRP and magnesium concentrations were measured between weeks 11 and 14 of gestation. Glucose tolerance test and fasting plasma insulin (FPI) measurement were performed between 24 and 28 weeks gestational age. To assess insulin sensitivity and β-cell function, Homeostatic Model Assessment Insulin Resistance (HOMA-IR), HOMA-β indices and Quantitative Insulin Sensitivity Check Index (QUICKI) were calculated and used.

Results: Out of the 126 who completed the study 19 (15%) were diagnosed as GDM. The median (interquartile) of FBG was significantly higher in women with GDM [81 (70–95) vs. 67(60–75) mg/dl; \( P = < 0.001 \)] compared to women without GDM. There was no significant difference in hs-CRP, serum magnesium, HOMA-IR, QUICKI and HOMA-β between women with GDM and women without GDM. No correlation was observed between body mass index (BMI), serum magnesium, hs-CRP, FBG and insulin levels.

Conclusions: First trimester hs-CRP and serum magnesium levels were not correlated with the later development of gestational diabetes in this setting.

Keywords: Magnesium, CRP, Pregnancy, Insulin resistance, Glucose, Sudan

Background

Gestational diabetes mellitus (GDM), according to American Diabetes Association (ADA) it is defined as a true diabetes that firstly recognized at first or second trimester and not proceeded by either type 1 or type 2 diabetes [1]. GDM among the major medical complication of pregnancy that can result in adverse health consequences for both the mother and the outcome [2]. Women with GDM are vulnerable to develop metabolic syndrome/type 2 diabetes later in life [3, 4]. Likewise, children born to mothers with GDM are threaten by glucose intolerance and obesity [5].

Screening to identify women at risk for GDM among pregnancies may allow more time for interventions and can yield a reduction in both GDM and its related adverse effects. Unfortunately, screening for GDM is commonly practiced after the 24th gestational week where there is a possible delay in implementing the desired/planned interventions e.g. pharmacological therapy, diet, and exercise [6]. Therefore, there is a need for screening methods for GDM in detecting the risk of GDM in the first trimester of the pregnancy. Metabolic studies have detected various biomarkers that may be useful in early
screening for GDM [7]. Low serum magnesium accompanied with high hs-CRP has been reported as a predictor for GDM in obese pregnant women [8]. It is known that magnesium promotes blood glucose reduction as it enhances the activity of the glucose transporter-4 [9]. Moreover, it is directly involved in signalling transduction of the insulin receptor [10]. On the other hand, high serum hs-CRP increased in response to inflammatory reactions owing to insulin resistance observed in GDM [11]. Recent findings suggest serum magnesium and C-reactive protein could be used as predictors for GDM [8, 12–19]. However, the results of these studies were variable and there is a need for further research in the different settings. Thus, the current study was conducted to investigate the correlation between serum magnesium, high sensitivity CRP (hs-CRP), glycaemic and insulin sensitivity index and to assess the performance of magnesium and hs-CRP in predicting GDM in the first trimester.

Materials and methods
A longitudinal cohort study was conducted at the antenatal care clinic of Saad Abualila Hospital (Khartoum, Sudan) during the period of January–November 2015. All women with singleton pregnancy, started antenatal care follow-up in the first trimester (≤14 weeks of gestation) were approached to participate in the study. Women with chronic disease e.g. thyroid disease, hypertension, renal disease, diabetes, liver disease and on medication were excluded from the study. After signing an informed consent, socio-demographic and obstetric characteristics were gathered by questionnaire (age, parity, gestational age, education, occupation and history of miscarriage). The weight and height were measured and body mass index (BMI) was computed (kg/m²). Pregnancy and its duration was confirmed by ultrasound operated in the clinic by a senior obstetrician. Then 5 ml of blood were withdrawn in EDTA tube, 2 mLs of it was used for hemogram and the rest were centrifuged and stored at –20 °C until the assay of hs-CRP level, which was performed by EUROIMMUN analyser I-2P (Luebeck, Germany). The same procedure was used to measure insulin level laterally in the third trimester. Atomic absorption spectrophotometry (SOLAAR, Atomic Absorption Spectrophotometer, Thermo Electron, Cambridge, UK) was used to determine levels of serum magnesium.

Then the enrolled women were followed in the antenatal care clinic every month. According to the hospital policy, the glucose tolerance test was performed at 24–28 weeks of gestation. Recommended blood glucose levels determined by International Association of Diabetes and Pregnancy Study Groups (IADPSG) and ADA were used to detect GDM among cases in this study. Which is described very briefly as one or more of the following blood glucose values met or exceeded; fasting blood glucose (FBG) ≥92 mg/dl, 1-h blood glucose was ≥180 mg/dl, and 2-h blood glucose ≥153 mg/dl, after 75-g oral glucose load [1, 19]. The study is adhered to STROBE guidelines [20].

Glucose oxidase test was used to assess the level of blood glucose (Shino-Test Corp. Tokyo, Japan). Insulin resistance was measured using the homeostasis model assessment (HOMA) of insulin resistance index (HOMA-IR) = fasting glucose level (mg/dl) × fasting insulin level (μU/ml) / 405 [21] and the quantitative insulin sensitivity check index (QUICKI) = 1 / [log fasting insulin level (μU/ml) + log fasting glucose level (mg/dl)] [22]. Insulin secretion was indicated by the HOMA of β-cell function (HOMA-β) (%) = 360 × fasting insulin level (μU/ml) / [fasting glucose level (mg/dl) – 63, [22].

Sample size calculated based on previous data [23], it was assumed that 13.9% of the pregnant women would experience gestational diabetes [23]. Allowing for 10% of participants to be lost to follow-up, a necessary sample size of 166 participants.

Statistics
Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA). Proportions of the studied variables were expressed in numbers (%). Continuous data were checked for normality using Shapiro-Wilk test. The means (standard deviations) or median (interquartile) were used to describe the studied variables if normally and abnormally distributed, respectively. Spearman correlation was conducted between BMI, magnesium, hs-CRP, FBG and insulin sensitivity indices. Student’s t-test and Mann-Whitney U test if the data were not normally distributed were used to evaluate the mean differences between the studied groups. P < 0.05 was considered statistically significant.

Result
One hundred and sixty women were initially enrolled, 126 (78.7%) women completed the follow-up, have complete data and analysed here. The main reason for the loss of follow-up was change of the address. The mean (SD) of gestational age in early pregnancy 10.2(2.4) and it was 26.5 (1.2) weeks at the time of the glucose tolerance testing.

General characteristics of the 126 enrolled women are shown in Table 1. Fifty-nine (46.8%) of the women were primiparae and 19 (15%) women had GDM. There was no correlation between BMI, serum magnesium, hs-CRP, FBG and insulin level in the enrolled pregnant women (n = 126), Table 2.
While FBG was significantly higher in women with GDM, BMI, serum magnesium, insulin, HOMA-IR, QUICKI and HOMA-β were not different in women with GDM \((n = 19)\) and women who had no GDM \((n = 107)\), Table 3.

**Discussion**

The current study shows no significant difference between serum magnesium, FBG and insulin resistance indices among women with GDM and women without GDM. Similarly, Nabouli et al. reported no significant difference in the serum magnesium level between women with GDM and women without GDM [16]. However, a significantly lower serum magnesium level, its association with insulin sensitivity and with fasting insulin in mothers with GDM have been reported before [8, 17, 18, 24]. Moreover, magnesium supplementations for magnesium deficient GDM patients result in a decrease of FBG, insulin, HOMA-IR, HOMA-B, hs-CRP and an increase of QUICKI [24]. Perhaps, hypomagnesemia lead to inadequate beta-cell compensation for the decrease in insulin sensitivity [25]. Interestingly, postpartum serum magnesium level was found to be a possible predictor for type 2 diabetes mellitus development in women with GDM [26]. We have previously observed a significantly lower median level of serum magnesium in diabetic patients with diabetic retinopathy compared with diabetic without diabetic retinopathy [27].

The hs-CRP level in the current study was not statistically different between women with GDM and women without GDM. This goes with Syngelaki et al. findings [14]. In contrast Fatema et al. and Ozgu-Erdinc et al. have recently reported a good performance (sensitivity and specificity) of hs-CRP in predicting GDM [12, 13]. Moreover, hs-CRP has been reported to be associated with insulin resistance, insulin index and GDM [15]. However, many reports claimed that CRP is positively correlated with pre-pregnancy BMI [28, 29]. Perhaps, our finding is partially attributed to the no difference observed in BMI and hs-CRP (which were expected to be higher in women with GDM). Yet Rota et al. [30] reported that the serum hs-CRP levels were significantly higher in GDM women despite no difference in the pre-pregnancy BMI. In the later study glucose intolerance and weight gain during pregnancy were the main factors which affect hs-CRP levels. In our study BMI, hs-CRP were taken in early pregnancy without follow-up values. This point (measurement in early pregnancy) could be another explanation of the non-significant difference in hs-CRP in our study. Inflammatory mediators secreted from adipose tissue and placenta can lead to escalating low-grade inflammation during pregnancy specially in the third trimester [31, 32]. It worth mentioning that, almost 75% of our patients have BMI < 30 and this finding is not astonishing as the prevalence of pregnant women who have BMI < 30 in Sudan is 79% [33]. Alternatively, perhaps in GDM the insulin resistance is an effect of impairment of insulin action, rather than insulin secretion (similar to type 2 DM patients) with declining of insulin receptors and impairing intracellular glucose transport [34].

**Conclusions**

In summary, we fail to show any prediction of first trimester hs-CRP and serum magnesium with the development of GDM in this setting. Also, no correlation has been observed between insulin hormone level and insulin resistance indices, magnesium levels and hs-CRP.

This study has many limitations, firstly; the current study recruited small sample size and under power. The

| Variables | Magnesium | hs-CRP | Insulin | FBG |
|-----------|-----------|--------|---------|-----|
| BMI       | 0.036     | 0.692  | -0.007  | 0.938 |
| Magnesium | 0.152     | 0.088  | -0.193  | 0.029 |
| hs-CRP    | 0.133     | 0.136  | -0.046  | 0.611 |
| Insulin   | -0.065    | 0.668  |         |      |
number of women with GDM is very low and comparison of them with women without GDM might not be reasonable. Secondly; other inflammatory markers e.g. cytokines were not measured and infections that might have effects on hs-CRP were not ruled out. Therefore, larger sample size with longitudinal study design is needed.

Abbreviations
- ADA: American Diabetes Association
- BMI: Body Mass Index
- FBG: Fasting Blood Glucose
- FPI: Fasting Plasma Insulin
- GDM: Gestational Diabetes Mellitus
- HOMA-IR: Homeostatic Model Assessment Insulin Resistance
- hs-CRP: High Sensitivity C-Reactive Protein
- IADPSG: International Association of Diabetes And Pregnancy Study Groups
- QUICKI: Quantitative Insulin Sensitivity Check Index
- SPSS: Statistical Package for the Social Sciences

Acknowledgements
The authors wish to thank the patients who participated in the study for their cooperation and patience.

Authors’ contributions
HZH and IA concepted and designed the study. WN, DAR and MAA conducted the study. DAR, MAA, HZH and IA shared in the statistical analyses. WN, HZH and IA share in drafting the paper. All of the authors drafted and approved this version of the paper.

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study received ethical clearance from Al-Neelain University Research Ethics Review Board in Al-Neelain University, Sudan. All participants provide consent for publication. The corresponding author on reasonable request.

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Availability of data and materials
Not applicable.

Funding
Not applicable.

Competing interests
One of the authors (Ishag Adam) is a member in BMC Pregnancy and Childbirth editorial board. Other authors declare that they have no competing of interests.

Author details
1Faculty of Medicine, Al-Neelain University, P.O Box 12702, 11111 Khartoum, Sudan. 2Faculty of Medicine, University of Khartoum, P.O Box 102, 11111 Khartoum, Sudan. 3Al-Neelain Institute for Medical Research (NIMR), Al-Neelain University, Khartoum, Sudan.

Received: 28 August 2017 Accepted: 25 July 2019
Published online: 16 August 2019

References
1. American Diabetes Association AD. 2. Classification and diagnosis of diabetes: standards of medical Care in Diabetes-2018. Diabetes Care. 2018;41(Supplement 1):S13–27.
2. Daif T, Yang W, Helder P, Pang B, Massoudi M. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes. 2014;37(12):3172–9.
3. Xu Y, Shen S, Sun L, Yang H, Jin B, Cao X. Metabolic Syndrome Risk after Gestational Diabetes: A Systematic Review and Meta-Analysis. Pasquali R, editor. PLoS One. 2014;9(1):e87863.
4. Rayanagoudar G, Hashi AA, Zamora J, Khan KS, Hitman GA, Thangaratinam S. Quantification of the type 2 diabetes risk in women with gestational diabetes: a systematic review and meta-analysis of 95,750 women. Diabetologia. 2016;59:1403–11.
5. Kim SY, England JL, Sharma JA, Njoroge T. Gestational diabetes mellitus and risk of childhood overweight and obesity in offspring: a systematic review. Exp Diabetes Res. 2011;2011:1–9.
6. Ray JG, Berger H, Lipscombe LL, Sermer M. Gestational prediabetes: a new term for early prevention? Indian J Med Res. 2010;132:251–5.
7. Kumru P, Arisoy R, Erdogdu E, Demirci O, Kavrut M, Ardic C, et al. Prediction of gestational diabetes mellitus at first trimester in low-risk pregnancies. Taiwan J Obstet Gynecol. 2016;65:815–20.
8. Mostafavi E, Nargesi AA, Ashbagh FA, Ghazizadeh Z, Heidari B, Mirrirmoproop H, Esteghamati A, Vigneron C, Nakhjavani M. Abdominal obesity and gestational diabetes: the interactive role of magnesium. Magnes Res. 2015;28:116–25.
9. Chen H-Y, Cheng F-C, Pan H-C, Hsu J-C, Wang M-F. Magnesium enhances exercise performance via increasing diabetes availability in the blood, muscle, and brain during exercise. PLoS One. 2014;9(1):e85486.
10. Gröber U, Schmidt J, Kästner K. Magnesium in prevention and therapy. Nutrients. 2015;7(9):2199–226.
11. Almoznino-Sarafian D, Berman S, Mor A, Shteinsnhaider M, Gorelik O, Tzur I, et al. Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration? Eur J Nutr. 2007;46(4):230–7.
12. Fatema N, Deeba F, Akter S, Sultana N, Nasrin B, Ali L, et al. CRP (C-reactive protein) in early pregnancy predictor for development of GDM. Mymensingh Med J. 2016;25:271–6.
13. Ozgu-Erdinc AS, Yilmaz S, Yeral MI, Seckin KD, Erkaya S, Danisman AN. Prediction of gestational diabetes mellitus in the first trimester: comparison of C-reactive protein, fasting plasma glucose, insulin and insulin sensitivity indices. J Materi Fetal Neonatal Med. 2014;2014:2014:320(1):258–63.
14. Syngelaki A, Visser GHA, Kriithinika K, Wright A, Nicolaides KH. First trimester screening for gestational diabetes mellitus by maternal factors and markers of inflammation. Metabolism. 2016;65:131–7.
15. Zhu C, Yang H, Geng Q, Ma Q, Long Y, Zhou C, et al. Association of Oxidative Stress Biomarkers with gestational diabetes mellitus in pregnant women: a case-control study. PLoS One. 2015;10:e0126490 Hribal ML, editor.

Table 3 Comparing median(interquartile) level of body mass index, hs-CRP, magnesium, glycaemic and insulin sensitivity indices between women with GDM and controls

| Variable                      | Women with GDM (n = 19) | Women without GDM (n = 107) | P     |
|-------------------------------|-------------------------|-----------------------------|-------|
| Body mass index, kg/m²        | 27.4 (23.3–31.2)        | 26.6 (24.3–29.6)            | 0.904 |
| Magnesium, mg/dl              | 1.8 (1.6–2.0)           | 1.7 (1.5–1.9)               | 0.245 |
| hs-CRP, mg/l                  | 1.8 (1.7–2.19)          | 1.82 (1.69–2.100)           | 0.912 |
| Insulin, μU/ml                | 4.1 (2.2–12.9)          | 6.1 (3.2–12.5)              | 0.338 |
| Fasting blood glucose, mg/dl  | 81.0 (70.0–95.0)        | 67.0 (60.0–75.5)            | < 0.001 |
| HOMA-IR                       | 1.1 (0.34–0.46)         | 0.96 (0.54–2.02)            | 0.980 |
| QUICKI                        | 0.37 (0.33–0.46)        | 0.38 (0.34–0.42)            | 0.980 |
| HOMA-β %                      | 93.0 (93.0–279.0)       | 102.6 (160.2–405.2)         | 0.602 |
16. Nabouli MR, Lassoued L, Bakri Z, Moghannem M. Modification of Total magnesium level in pregnant Saudi women developing gestational diabetes mellitus. Diabetes Metab Syndr Clin Res Rev. 2016;10:183–5.

17. Goker Tasdemir U, Tasdemir N, Kilic S, Abali R, Celik C, Gulermanc HC. Alterations of ionized and Total magnesium levels in pregnant women with gestational diabetes mellitus. Gynecol Obstet Invest. 2015;79:19–24.

18. Del Gobbo LC, Song Y, Eljin RJ, Melzer SJ, Egeland GM. Gestational glucose intolerance modifies the association between magnesium and glycemic variables in mothers and daughters 15 years post-partum. Magnes Res. 2012;25:54–63.

19. International Association of Diabetes and Pregnancy Study Groups Consensus Panel MBE, Gabibe SC, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676–82.

20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–49.

21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.

22. Katz A, Namibi SS, Mather K, Baron AD, Vollmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.

23. Macaulay S, Dunger DB, Norris SA. Gestational diabetes mellitus in Africa: a systematic review. PLoS One. 2014;9(6):e97871.

24. Asemi Z, Karamali M, Jamilian M, Foroozanfard F, Bahrani F, Heidarzadeh Z, et al. Magnesium supplementation affects metabolic status and pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2015;102:222–9.

25. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. Failure of beta-cell function for compensate variation in insulin sensitivity in hypomagnesemic subjects. Magnes Res. 2009;22:151–6.

26. Yang SJ, Hwang SY, Baik SH, Lee KW, Narn MS, Park YS, et al. Serum magnesium level is associated with type 2 diabetes in women with a history of gestational diabetes mellitus: the Korea National Diabetes Program Study. J Korean Med Sci. 2014;29:84.

27. Hamdan HZ, Nasser NM, Adam AM, Saleem MA, Elamin MI. Serum magnesium, Iron and ferritin levels in patients with diabetic retinopathy attending Makka eye complex, Khartoum, Sudan. Biol Trace Elem Res. 2015;165(1):30–4.

28. Shin D, Hur J, Cho E-H, Chung H-K, Shivasappa N, Wirth MD, et al. Pre-pregnancy body mass index is associated with dietary inflammatory index and C-reactive protein concentrations during pregnancy. Nutrients. 2017;9(4):E351.

29. Chen X, Scholl TO, Stein TP. Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women: the Camden study. Diabetes Care. 2006;29:1077–82 Cited 9 Apr 2017.

30. Rota S, Yildirim B, Kaleli B, Aybek H, Duman K, Kaptanoğlu B. C-reactive protein levels in non-obese pregnant women with gestational diabetes. Tohoku J Exp Med. 2005;206:341–5.

31. Desoye G, Hauguel-de Mouzon S. The human placenta in gestational diabetes mellitus. The insulin and cytokine network. Diabetes Care. 2007;30(Suppl 2):S120–6.

32. Viachnis N, Beltosso P, Sifakis S, Dafopoulos K, Sirestisidis C, Pappa KI, et al. Role of adipokines and other inflammatory mediators in gestational diabetes mellitus and previous gestational diabetes mellitus. Int J Endocrinol. 2012;2012:949748.

33. Rayis DA, Abbaker AO, Salih Y, Adam I. Obesity and pregnancy outcome in Khartoum, Sudan. Int J Gynecol Obstet. 2011;113(2):160–1.

34. Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP, Gomes KB. The linkage between inflammation and type 2 diabetes mellitus. Diabetes Res Clin Pract. 2013;99(2):85–92.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.